Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
AML1-ETO meets JAK2: clinical evidence for the two hit model of leukemogenesis from a myeloproliferative syndrome progressing to acute myeloid leukemia.
Schneider F, Bohlander SK, Schneider S, Papadaki C, Kakadyia P, Dufour A, Vempati S, Unterhalt M, Feuring-Buske M, Buske C, Braess J, Wandt H, Hiddemann W, Spiekermann K. Schneider F, et al. Among authors: papadaki c. Leukemia. 2007 Oct;21(10):2199-201. doi: 10.1038/sj.leu.2404830. Epub 2007 Jul 12. Leukemia. 2007. PMID: 17625612 No abstract available.
LKB1 Loss Correlates with STING Loss and, in Cooperation with β-Catenin Membranous Loss, Indicates Poor Prognosis in Patients with Operable Non-Small Cell Lung Cancer.
Lagoudaki ED, Koutsopoulos AV, Sfakianaki M, Papadaki C, Manikis GC, Voutsina A, Trypaki M, Tsakalaki E, Fiolitaki G, Hatzidaki D, Yiachnakis E, Koumaki D, Mavroudis D, Tzardi M, Stathopoulos EN, Marias K, Georgoulias V, Souglakos J. Lagoudaki ED, et al. Among authors: papadaki c. Cancers (Basel). 2024 May 10;16(10):1818. doi: 10.3390/cancers16101818. Cancers (Basel). 2024. PMID: 38791897 Free PMC article.
Correction: Prediction of outcome in patients with non-small cell lung cancer treated with second line PD-1/PDL-1 inhibitors based on clinical parameters: Results from a prospective, single institution study.
Rounis K, Makrakis D, Papadaki C, Monastirioti A, Vamvakas L, Kalbakis K, Gourlia K, Xanthopoulos I, Tsamardinos I, Mavroudis D, Agelaki S. Rounis K, et al. Among authors: papadaki c. PLoS One. 2023 Nov 9;18(11):e0294382. doi: 10.1371/journal.pone.0294382. eCollection 2023. PLoS One. 2023. PMID: 37943834 Free PMC article.
Correction: Effect of body tissue composition on the outcome of patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors.
Makrakis D, Rounis K, Tsigkas AP, Georgiou A, Galanakis N, Tsakonas G, Ekman S, Papadaki C, Monastirioti A, Kontogianni M, Gioulbasanis I, Mavroudis I, Agelaki S. Makrakis D, et al. Among authors: papadaki c. PLoS One. 2023 Nov 9;18(11):e0294384. doi: 10.1371/journal.pone.0294384. eCollection 2023. PLoS One. 2023. PMID: 37943779 Free PMC article.
Effect of body tissue composition on the outcome of patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors.
Makrakis D, Rounis K, Tsigkas AP, Georgiou A, Galanakis N, Tsakonas G, Ekman S, Papadaki C, Monastirioti A, Kontogianni M, Gioulbasanis I, Mavroudis D, Agelaki S. Makrakis D, et al. Among authors: papadaki c. PLoS One. 2023 Feb 10;18(2):e0277708. doi: 10.1371/journal.pone.0277708. eCollection 2023. PLoS One. 2023. PMID: 36763597 Free PMC article.
TLR4 and pSTAT3 Expression on Circulating Tumor Cells (CTCs) and Immune Cells in the Peripheral Blood of Breast Cancer Patients: Prognostic Implications.
Papadaki MA, Monastirioti A, Apostolopoulou CA, Aggouraki D, Papadaki C, Michaelidou K, Vassilakopoulou M, Alexakou K, Mavroudis D, Agelaki S. Papadaki MA, et al. Among authors: papadaki c. Cancers (Basel). 2022 Feb 18;14(4):1053. doi: 10.3390/cancers14041053. Cancers (Basel). 2022. PMID: 35205801 Free PMC article.
56 results